Clinical Trial Update: Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant [Phase 3]

View source ↗

Summary

A Phase 3 trial of moxifloxacin to prevent bacterial infections in patients who have undergone a donor stem cell transplant was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leukemia
• Lymphoma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Neuroblastoma
• Ovarian Cancer

Drugs mentioned

• Avelox (moxifloxacin)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Breast Cancer, Chronic Myeloproliferative Disorders | Phase 3 | Status: TERMINATED